Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aanchal Sugandh

EXPLAINED: Dear merck stock fans mark your calendars for october 29 | Vintage Vibes

Merck (MRK), known as MSD outside the United States and Canada, has earned a heavyweight spot in the pharmaceutical industry. Its blockbuster cancer immunotherapy Keytruda brought in $31.7 billion in 2025, giving the company a powerful revenue engine alongside its broader portfolio of oncology treatments, vaccines, and cardiometabolic medicines.

Now, the pharmaceutical giant faces another major test as it prepares to report its Q3 FY2026 financial results before the market opens on Thursday, Oct. 29. The results would show whether Keytruda can continue doing the heavy lifting, particularly as Merck expands its subcutaneous formulation, Keytruda Qlex, which delivers the treatment through an injection under the skin.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.